Product Description
ONC206 is a DRD2 antagonist and ClpP agonist with nanomolar potency that demonstrates enhanced non-competitive DRD2 antagonism relative to ONC201 and disruption of DRD2 homodimers. ONC206 exhibits a distinct gene expression profile as well as single agent and combinatorial efficacy with ONC201 in cells with acquired resistance to ONC201. ONC206 is effective in preclinical models of difficult-to-treat neuroendocrine tumors and high-grade gliomas. (Sourced from: https://www.chimerix.com/our-pipeline/imipridones/onc206/)
Mechanisms of Action: D2 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Jazz
Company Location: Europe
Company CEO: Bruce C. Cozadd
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Switzerland, United States
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
- Clinical Outcomes Reported - Chimerix presented P1 Glioma results on 2024-11-22 for ONC-206
- Clinical Outcomes Reported - Chimerix announced they will present P1 Oncology Solid Tumor Unspecified results in 3Q24 for ONC-206
- Clinical Outcomes Reported - Chimerix announced they will present P0 Oncology Solid Tumor Unspecified results in 2H24 for ONC-206
Highest Development Phases
Phase 2: Paraganglioma|Pheochromocytoma
Phase 1: Astrocytoma|Ependymoma|Glioblastoma|Glioma|Gliosarcoma|Medulloblastoma|Meningioma|Oligodendroglioma|Pinealoma|Primitive Neuroectodermal Tumors|Rhabdoid Tumor
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04732065 |
PNOC023 | P1 |
Recruiting |
Glioblastoma|Ependymoma|Glioma |
2027-05-31 |
12% |
2024-08-08 |
|
NCT04541082 |
ONC206-001 | P1 |
Recruiting |
Rhabdoid Tumor|Medulloblastoma|Glioblastoma|Pinealoma|Primitive Neuroectodermal Tumors|Gliosarcoma|Oligodendroglioma|Ependymoma|Meningioma|Astrocytoma |
2026-07-01 |
50% |
2025-12-18 |
Primary Completion Date|Primary Endpoints|Treatments |
NCT07282587 |
ONC206-002 | P2 |
Not yet recruiting |
Paraganglioma|Pheochromocytoma |
2028-12-15 |
12% |
2025-12-16 |
Primary Endpoints|Treatments |